Sana Biotechnology (NASDAQ:SANA) Raised to Buy at TD Cowen

Sana Biotechnology (NASDAQ:SANA) was upgraded by investment analysts at TD Cowen from a “hold” rating to a “buy” rating in a report issued on Wednesday,Benzinga reports.

Several other research firms have also recently weighed in on SANA. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Sana Biotechnology in a research report on Wednesday, November 27th. JMP Securities cut shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.50.

Sana Biotechnology Stock Down 5.7 %

Sana Biotechnology stock opened at $1.65 on Wednesday. Sana Biotechnology has a 12 month low of $1.52 and a 12 month high of $12.00. The stock has a market cap of $368.39 million, a price-to-earnings ratio of -1.18 and a beta of 1.45. The business has a 50 day moving average price of $2.38 and a two-hundred day moving average price of $4.07.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. On average, analysts expect that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sana Biotechnology

Several institutional investors have recently bought and sold shares of SANA. Wilmington Savings Fund Society FSB acquired a new stake in shares of Sana Biotechnology in the third quarter valued at approximately $29,000. Stifel Financial Corp bought a new position in Sana Biotechnology in the third quarter valued at $43,000. EP Wealth Advisors LLC bought a new position in Sana Biotechnology in the third quarter valued at $45,000. Blue Trust Inc. increased its stake in Sana Biotechnology by 1,246.6% in the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock valued at $55,000 after buying an additional 12,154 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. bought a new stake in Sana Biotechnology during the 3rd quarter worth about $67,000. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.